Table 4.
Antihyperglycemic activity of repeated daily doses of Calpurnia aurea leaf extract in STZ-induced diabetic mice.
| Group | Fasting blood glucose level (mg/dl) | Percent reduction in baseline BGL | |||
|---|---|---|---|---|---|
| Baseline | 7th day | 14th day | 7th day | 14th day | |
| Diabetic control | 394.11 ± 31.0n3 | 383.67 ± 45.83n3 | 387.00 ± 47.77n3 | 2.60% | 1.80% |
| CALE 100 mg/kg | 377.72 ± 43.57n3 | 251.39 ± 28.86a1 n2 | 250.44 ± 28.84a1 β1 n1 | 33.45% | 33.69% |
| CALE 200 mg/kg | 314.39 ± 31.99n2 | 243.56 ± 24.58a1 n1 | 239.94 ± 35.81a1 n1 | 22.53% | 23.68% |
| CALE 400 mg/kg | 342.67 ± 58.07n3 | 252.72 ± 14.43a1 n2 | 250.61 ± 14.42a1 n1 | 26.25% | 26.87% |
| GLC 5 mg/kg | 368.50 ± 43.02n3 | 145.56 ± 26.72a3 β3 | 136.67 ± 26.41a3 β3 | 60.49% | 62.91% |
| Normal control | 76.83 ± 2.51 | 77.67 ± 2.50 | 78.67 ± 2.75 | -1.09% | -2.40% |
Each value represents mean ± SEM; n=6 for each group. aCompared to the diabetic control, ncompared to the normal control, and βcompared to baseline blood glucose level. 1p < 0.05, 2p < 0.01, and 3p < 0.001. CALE = Calpurnia aurea leaf extract and GLC = glibenclamide.